Brooklyn-based biotechnology company Cresilon's Traumagel, a gel that can control moderate to severe bleeding in seconds, has received the US Food and Drug Administration clearance. The algae-derived gel rapidly stops bleeding at the point of care and halts a life-threatening haemorrhage. It comes in a pre-filled syringe and requires no manual pressure on the wound to create a blood clot.